Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tenaya Therapeutics Inc

1.98
-0.1200-5.71%
Post-market: 1.980.00000.00%16:04 EDT
Volume:8.11M
Turnover:16.83M
Market Cap:322.69M
PE:-2.21
High:2.20
Open:2.17
Low:1.93
Close:2.10
52wk High:4.01
52wk Low:0.3600
Shares:162.98M
Float Shares:152.50M
Volume Ratio:1.30
T/O Rate:5.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8943
EPS(LYR):-1.3101
ROE:-85.21%
ROA:-45.11%
PB:3.23
PE(LYR):-1.51

Loading ...

Tenaya Therapeutics to Participate in HC Wainwright Genetic Medicines Virtual Conference

Reuters
·
Oct 10

Tenaya Therapeutics (TNYA): Evaluating Valuation Following CEO’s Spotlight at Cell & Gene Meeting on the Mesa

Simply Wall St.
·
Oct 10

Tenaya Therapeutics to Participate in Upcoming October Investor Conferences

GlobeNewswire
·
Oct 03

Tenaya Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Sep 19

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 19

Tenaya Therapeutics to Participate in Morgan Stanley Annual Global Healthcare Conference

Reuters
·
Sep 03

Tenaya Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 02

Tenaya Therapeutics Unveils Interim Data from MyClimb™ Study at ESC 2025, Offering New Insights into Pediatric MYBPC3-associated HCM Risks

Reuters
·
Aug 31

Tomohiro Higa, SVP of Finance, Reports Disposal of Tenaya Therapeutics Common Shares

Reuters
·
Aug 19

Ali Faraz, CEO, Reports Disposal of Common Shares of Tenaya Therapeutics Inc

Reuters
·
Aug 19

Tenaya Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference

Reuters
·
Aug 08

Tenaya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 07

Tenaya Therapeutics Q2 net loss of $23.3 narrows

Reuters
·
Aug 07

Tenaya Therapeutics Q2 Basic EPS USD -0.14

THOMSON REUTERS
·
Aug 07

Tenaya Therapeutics Q2 Operating Expenses USD 24.082 Million

THOMSON REUTERS
·
Aug 07

Tenaya Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview

Reuters
·
Jul 31

Tenaya Therapeutics Inc: Plans to Report Longer-Term Follow-up Data From Cohort 1 and Initial Data From Cohort 2 in Q4 of This Year

THOMSON REUTERS
·
Jul 30

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

GlobeNewswire
·
Jul 30

Tenaya Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
May 31

Tenaya Therapeutics' SVP Finance Tomohiro Higa Reports Disposal of Common Shares

Reuters
·
May 17